FDA approves Orzeyful for adults with narcolepsy type 1
The FDA approved Orzeyful tablets for adults with narcolepsy type 1, a rare sleep disorder that affects an estimated 1 in 2,000 people in the United States.
Regulatory
CISA adds exploited JetBrains TeamCity flaw to KEV Catalog
CISA has added CVE-2026-63077, a JetBrains TeamCity deserialization flaw, to its Known Exploited Vulnerabilities Catalog after evidence of active exploitation.
STX deploys Eventus Validus for trade surveillance on planned regulated market
STX said it deployed Eventus Validus for trade surveillance as it prepares to launch a regulated event contracts market.
Mangoceuticals gets 180-day Nasdaq extension to regain bid-price compliance
Mangoceuticals said Nasdaq granted a 180-day extension, giving the company until Feb. 1, 2027 to regain compliance with the exchange’s minimum bid-price rule.
CISA adds three exploited vulnerabilities to its Known Exploited Vulnerabilities Catalog
CISA added three vulnerabilities to its Known Exploited Vulnerabilities Catalog after finding evidence of active exploitation and reiterated federal patching guidance under BOD 26-04.
CISA warns of Bluetooth flaw in Acrisure KARR BT and DR-100 systems
CISA warned that a high-severity Bluetooth authentication flaw in Acrisure KARR BT and DR-100 systems could let an attacker issue unauthorized vehicle commands. Acrisure released a firmware update on July 20, 2026.
CISA warns of Thermo Fisher analyzer flaw that could alter DNA data files
CISA published an advisory on Aug. 4 about CVE-2026-17583 in several Thermo Fisher Applied Biosystems Genetic Analyzer products, warning that tampered .fsa and .hid files could lead to inaccurate DNA results.